Advertisement

Hidradenitis Suppurativa

  • Christos C. Zouboulis
  • Mankul Goyal
Chapter

Abstract

Hidradenitis suppurativa (HS) or acne inversa is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicles that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the body, most commonly the axillae, inguinal, and anogenital regions [1]. The disease affects mainly young adults with a female predominance (female to male ratio 2.4–3.3:1). Among the various populations and skin types, prevalence and incidence often differ, but there are no differences in major clinical characteristics. Spontaneous resolution of the disease is rare. Medical treatment targets the inflammatory response, and surgical intervention reduces the burden of the disease offering an overall better outcome. In addition, lifestyle modifications like smoking cessation and weight loss play an important role in improving the prognosis of HS. In recent studies, patients with hidradenitis suppurativa, blistering diseases, leg ulcers, psoriasis, and eczemas had the highest risk for reduction of health-related quality of life among all other non-tumor dermatological conditions [2].

References

  1. 1.
    Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–44.CrossRefPubMedGoogle Scholar
  2. 2.
    Balieva F, Kupfer J, Lien L, et al. The burden of common skin diseases assessed with the EQ5D™: a European multicentre study in 13 countries. Br J Dermatol. 2017;176:1170–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.CrossRefPubMedGoogle Scholar
  5. 5.
    Albares MP, Belinchón I, Ramos JM, et al. Estudio epidemiológico de la patología cutánea en la población inmigrante de Alicante. Actas Dermosifiliogr. 2012;103:214–22.CrossRefPubMedGoogle Scholar
  6. 6.
    Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Garg A, Kirby JS, Lavian J et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis Suppurativa in the United States. JAMA Dermatol. 2017;153:760–4.Google Scholar
  8. 8.
    Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97–103.CrossRefPubMedGoogle Scholar
  9. 9.
    Garg A, Lavian J, Lin G, et al. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77:118–22.CrossRefPubMedGoogle Scholar
  10. 10.
    Vlassova N, Kuhn D, Okoye GA. Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis. Acta Derm Venereol. 2015;95:990–1.CrossRefPubMedGoogle Scholar
  11. 11.
    von Laffert M, Stadie V, Wohlrab J, et al. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367–71.CrossRefGoogle Scholar
  12. 12.
    Ingram JR. The genetics of hidradenitis suppurativa. Dermatol Clin. 2016;34:23–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(suppl 1):S8–S11.CrossRefPubMedGoogle Scholar
  14. 14.
    Chen S, Mattei P, You J, et al. γ-Secretase mutation in an African American family with hidradenitis suppurativa. JAMA Dermatol. 2015;151:668–70.CrossRefPubMedGoogle Scholar
  15. 15.
    Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17:455–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Karagiannidis I, Nikolakis G, Zouboulis CC. Endocrinologic aspects of hidradenitis suppurativa. Dermatol Clin. 2016;34:45–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Nikolakis G, Join-Lambert O, Karagiannidis I, et al. Bacteriology of hidradenitis suppurativa/acne inversa: a review. J Am Acad Dermatol. 2015;73(suppl 1):S12–8.Google Scholar
  18. 18.
    Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Peters NJ, Kapoor R. Gluteal and perianal hidradenitis suppurativa associated with tuberculosis. Indian J Surg. 2012;74:194–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Patnaik S, Mohanty I, Panda P, et al. Disseminated mycobacterium chelonae infection: complicating a case of hidradenitis suppurativa. Ind Dermatol Online J. 2013;4:336–9.CrossRefGoogle Scholar
  21. 21.
    Fabbrocini G, Ruocco E, De Vita V, et al. Squamous cell carcinoma arising in long-standing hidradenitis suppurativa: an overlooked facet of the immunocompromised district. Clin Dermatol. 2017;35:225–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Zouboulis CC, del Marmol V, Mrowietz U, et al. Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology. 2015;231:184–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Zouboulis CC, Tzellos T, Kyrgidis A et al. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. Br J Dermatol. 2017; 177:1401–9.Google Scholar
  25. 25.
    Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk RK, Roenigk Jr HH, editors. Dermatologic surgery. Principles and practice. 2nd ed. New York: Marcel Dekker; 1996. p. 623–45.Google Scholar
  26. 26.
    Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173:464–70.CrossRefPubMedGoogle Scholar
  27. 27.
    Tzellos T, Zouboulis CC, Gulliver W, et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015;173:1142–55.CrossRefPubMedGoogle Scholar
  28. 28.
    Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinology. 2010;2:9–16.CrossRefGoogle Scholar
  29. 29.
    Egeberg A, Jemec GBE, Kimball AB, et al. Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. J Invest Dermatol. 2017;137:1060–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am J Clin Dermatol. 2017;18:555–62.CrossRefPubMedGoogle Scholar
  31. 31.
    Zouboulis CC, Desai N, Emtestam L, et al. Partial actualization of the European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. Exp Dermatol. 2016;25(suppl 2):13.Google Scholar
  32. 32.
    Bartalesi F, Bartoloni A, Bisoffi Z, et al. The emerging problem of biological treatment in migrant and travelling populations: it is time to extend guidelines for the screening of infectious diseases. Ann Rheum Dis. 2014;73:794–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Janse I, Bieniek A, Horváth B, et al. Surgical procedures in hidradenitis suppurativa. Dermatol Clin. 2016;34:97–109.CrossRefPubMedGoogle Scholar
  34. 34.
    Kromann CB, Ibler KS, Kristiansen VB, et al. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94:553–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Kromann CB, Deckers IE, Esmann S, et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171:819–24.CrossRefPubMedGoogle Scholar
  36. 36.
    Danby FW. Diet in the prevention of hidradenitis suppurativa (acne inversa). J Am Acad Dermatol. 2015;73(suppl 1):S52–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Departments of Dermatology, Venereology, Allergology and ImmunologyDessau Medical Center, Brandenburg Medical School Theodor FontaneDessauGermany
  2. 2.Delhi Dermatology Group, Kubba ClinicNew DelhiIndia

Personalised recommendations